Sage Therapeutics, Inc. financial data

Symbol
SAGE on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 981 % -4.26%
Debt-to-equity 12.1 % +12.3%
Return On Equity -68.2 % -17.5%
Return On Assets -60.8 % -16.1%
Operating Margin -1.05K % -56.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.5M shares +2.29%
Common Stock, Shares, Outstanding 61.4M shares +2.19%
Entity Public Float 590M USD -76.1%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.8M shares +1.55%
Weighted Average Number of Shares Outstanding, Diluted 60.8M shares +1.55%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41.2M USD -52.3%
Research and Development Expense 226M USD -36.6%
Operating Income (Loss) -432M USD +25.4%
Net Income (Loss) Attributable to Parent -401M USD +26%
Earnings Per Share, Basic -6.59 USD/shares +27.2%
Earnings Per Share, Diluted -6.59 USD/shares +27.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 81M USD +14.1%
Marketable Securities, Current 423M USD -37.9%
Accounts Receivable, after Allowance for Credit Loss, Current 9.13M USD -89%
Assets, Current 531M USD -38.9%
Property, Plant and Equipment, Net 890K USD -53.7%
Operating Lease, Right-of-Use Asset 10.8M USD +141%
Other Assets, Noncurrent 2.83M USD -56.8%
Assets 547M USD -38%
Accounts Payable, Current 12.7M USD +23.1%
Employee-related Liabilities, Current 14.8M USD -30.5%
Accrued Liabilities, Current 57.6M USD -14.4%
Liabilities, Current 71.6M USD -13.5%
Operating Lease, Liability, Noncurrent 10.5M USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 82.1M USD -0.74%
Accumulated Other Comprehensive Income (Loss), Net of Tax 244K USD
Retained Earnings (Accumulated Deficit) -2.97B USD -15.6%
Stockholders' Equity Attributable to Parent 465M USD -41.8%
Liabilities and Equity 547M USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD +75.4%
Net Cash Provided by (Used in) Financing Activities 1.56M USD -41.7%
Net Cash Provided by (Used in) Investing Activities 139M USD -28.4%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 61.4M shares +2.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 103M USD +135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82.5M USD +14%
Deferred Tax Assets, Valuation Allowance 797M USD +8.37%
Deferred Tax Assets, Gross 797M USD +8.37%
Operating Lease, Liability 11.8M USD +129%
Depreciation 336K USD +4.03%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -400M USD +24.9%
Lessee, Operating Lease, Liability, to be Paid 15.4M USD
Property, Plant and Equipment, Gross 1.67M USD -82.2%
Operating Lease, Liability, Current 1.32M USD -74.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.46M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +40%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.58M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.06M USD
Deferred Tax Assets, Operating Loss Carryforwards 491M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 8.28M USD +6.91%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.14M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 54.5M USD -25.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%